Young E. Whang
YOU?
Author Swipe
View article: [Retracted] Promoter methylation of RASSF1A modulates the effect of the microtubule‑targeting agent docetaxel in breast cancer
[Retracted] Promoter methylation of RASSF1A modulates the effect of the microtubule‑targeting agent docetaxel in breast cancer Open
Following the publication of this paper, and a corrigendum that was subsequently published to take account of anomalies that were identified with the assembly of western blot data in Fig. 5B (doi: 10.3892/ijo.2017.3900), a concerned reader…
View article: Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer.
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer. Open
BACKGROUND: Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome. OBJECTIVE: We conducted a s…
View article: Supplemental Table 4 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 4 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 4. Patient Demographics.
View article: Supplemental Table 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 1. Treatment Modifications.
View article: Supplemental Table 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 2. SAEs per arm.
View article: Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Figure 2 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Figure 2. Outcomes for primary and exploratory arms.
View article: Supplemental Figure 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Figure 1 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Figure 1. PFS for primary arms.
View article: Data from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Data from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Purpose:Deleterious germline/somatic homologous recombination repair mutations (HRRm) are present in ∼25% of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinically, poly(ADP-ribose) polymerase (PARP) inhibitio…
View article: Supplemental Table 3 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 3 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 3. Reasons for not crossing over per arm.
View article: Supplemental Table 5 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 5 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 5. Treatment-Related AEs in Exploratory Arms.
View article: Supplemental Table 6 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Supplemental Table 6 from Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) Open
Supplemental Table 6. Representativeness of Study Patients.
View article: Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report Open
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3-targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome bu…
View article: Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.
Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. Open
For over 70 years, androgen deprivation therapy (ADT) has been a fundamental treatment paradigm for advanced prostate cancer. Despite initial effectiveness, castration resistant prostate cancer (CRPC) develops in virtually all patients whi…
View article: Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the asso…
View article: FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Distributions of pain at study enrollment by race. A, Distributions of scores on the EORTC pain scale by race. B, Distributions of scores on the average pain scale by race. C, Distributions of scores on the worst pain scale by race. D, Dis…
View article: Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer Open
Background: Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome. Objective: We conducted a s…
View article: Supplementary Figure S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Figure S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Kaplan-Meier survival curve by disease state at study enrollment
View article: Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Further information guiding the choice of methods and a glossary of technical terms
View article: Supplementary Table S3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Table S3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Correlation coefficients between baseline pain scale scores
View article: Supplementary Table S6 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Table S6 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Baseline EORTC pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure
View article: Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Further information guiding the choice of methods and a glossary of technical terms
View article: Supplementary Table S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Table S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Number of participants receiving each therapy category between 3 months prior to enrollment and any time after enrollment stratified by disease state and self-reported race (N=19 therapy categories), N (%)
View article: Supplementary Table S9 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Table S9 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Baseline bone pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure
View article: Supplementary Table S8 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Table S8 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Baseline worst pain scale Cox model results from sensitivity analysis for missing indicator values during MICE procedure
View article: TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Cohort demographic and clinical characteristics by self-reported race (N = 879), 2017–2023
View article: TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Average pain at study enrollment by disease state at enrollment and self-reported race (N = 4 pain scales)
View article: Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Selection of study participants exclusion flowchart
View article: TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
HRs and 95% CIs for the association between baseline and longitudinal pain scales and death, IRONMAN Registry 2017–2023 (N = 879; 137 deaths in White participants, 37 deaths in Black participants)
View article: FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Distributions of pain at study enrollment by race. A, Distributions of scores on the EORTC pain scale by race. B, Distributions of scores on the average pain scale by race. C, Distributions of scores on the worst pain scale by race. D, Dis…
View article: Supplementary Figure S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States
Supplementary Figure S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States Open
Longitudinal observation status of questionnaires and reasons for being off-study throughout follow-up